stockportfolio.pro
Axsome Therapeutics, Inc. (AXSM)
Healthcare · Biotechnology · NasdaqGM
Axsome Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $50.04M | $270.60M | $385.69M | $638.50M |
| Gross profit | — | — | — | — | — | — | $44.84M | $244.53M | $352.39M | $591.02M |
| Net income | $-27.20M | $-28.94M | $-30.97M | $-68.35M | $-102.90M | $-130.40M | $-187.13M | $-239.24M | $-287.22M | $-183.17M |
| Net margin | — | — | — | — | — | — | -374.0% | -88.4% | -74.5% | -28.7% |
Source: Axsome Therapeutics, Inc. SEC filings (10-K). 12 years of history available in the interactive view.
Explore 12 years of Axsome Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AXSM in your portfolio →
Axsome Therapeutics, Inc. financial history by metric
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Axsome Therapeutics, Inc. — frequently asked questions
What is Axsome Therapeutics, Inc.'s revenue?
Axsome Therapeutics, Inc. (AXSM) reported revenue of $638.50M for fiscal year 2025, up 65.5% from the prior year, according to its SEC filings.
Is Axsome Therapeutics, Inc. profitable?
No — AXSM reported a net loss of $-183.17M in fiscal 2025.
What is AXSM's P/E ratio?
Axsome Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Axsome Therapeutics, Inc. have?
As of fiscal year 2025, AXSM carried roughly $187.75M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Axsome Therapeutics, Inc.'s gross margin?
AXSM's gross margin was 92.6% in fiscal 2025 — gross profit of $591.02M on revenue of $638.50M.
What is Axsome Therapeutics, Inc.'s market cap?
Axsome Therapeutics, Inc. (AXSM) has a market capitalization of about $13.02B, based on the latest data in our nightly-refreshed cache.
When does Axsome Therapeutics, Inc.'s fiscal year end?
AXSM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Axsome Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.